Compare Cytokinetics Inc (CYTK) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares Ultra QQQ ETF — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while ProShares Ultra QQQ ETF trades at $92.22. Which is the better fit depends on your goals.
| CYTK | QLD | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $100.53 |
52-Week Low | $34.31 | $57.16 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
QLD, the ProShares Ultra QQQ ETF, trades at $92.2, up 2.3% today, reflecting strong bullish momentum. Technical indicators show a bullish moving average consensus and key support at $91, with resistance at $93. Recent institutional buying, including a 29.4% stake increase by 180 Wealth Advisors in Q2 2026, underscores confidence. The ETF has delivered over 10,000% total return since inception, though its leveraged structure amplifies volatility.
The outlook for QLD is cautiously optimistic, driven by tech sector strength and tactical ETF demand. However, risks include amplified losses during market downturns, with a historical maximum drawdown of 63.80%. Investors should weigh the potential for outsized gains against the inherent volatility of daily leveraged products in a shifting economic landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
